Annual report [Section 13 and 15(d), not S-K Item 405]

IN-LICENSING AND ACQUISITION - Narrative (Details)

v3.25.4
IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 31, 2024
Jul. 31, 2022
Dec. 31, 2025
Dec. 31, 2022
Dec. 31, 2024
Asset Acquisition [Line Items]            
Acquisition-related liabilities       $ 0   $ 5,000
Intangible assets, estimated useful life (in years)       10 years 6 months 14 days    
Accounts payable       $ 7,191   3,339
Forma            
Asset Acquisition [Line Items]            
Upfront fee     $ 2,000      
Research and development         $ 2,000  
Forma | Commercial Milestones            
Asset Acquisition [Line Items]            
Potential payments     165,500      
Forma | Development and Regulatory Milestones            
Asset Acquisition [Line Items]            
Potential payments     $ 67,500      
Forma | Achievement of Certain Near-Term Regulatory Milestone            
Asset Acquisition [Line Items]            
Research and development         2,500  
Gavreto            
Asset Acquisition [Line Items]            
Intangible assets, estimated useful life (in years)       12 years    
Rezlidhia            
Asset Acquisition [Line Items]            
Intangible assets, estimated useful life (in years)       14 years    
Rezlidhia | FDA Approval and First Commercial Sale of Product            
Asset Acquisition [Line Items]            
Accounts payable         $ 15,000  
Blueprint            
Asset Acquisition [Line Items]            
Acquisition payment $ 15,000          
Blueprint | Gavreto            
Asset Acquisition [Line Items]            
Asset acquisition, expected price $ 15,000          
Acquisition payment   $ 10,000        
Acquisition-related liabilities       $ 5,000   $ 5,000
Blueprint | Gavreto | Minimum            
Asset Acquisition [Line Items]            
Potential tiered royalties (as a percent) 10.00%          
Blueprint | Gavreto | Maximum            
Asset Acquisition [Line Items]            
Potential tiered royalties (as a percent) 30.00%          
Blueprint | Gavreto | First Commercial Sale            
Asset Acquisition [Line Items]            
Asset acquisition, expected price $ 10,000          
Blueprint | Gavreto | First Anniversary of the Closing Date            
Asset Acquisition [Line Items]            
Asset acquisition, expected price 5,000          
Blueprint | Gavreto | Commercial Milestones            
Asset Acquisition [Line Items]            
Potential milestone payments 97,500          
Blueprint | Gavreto | Regulatory Milestones            
Asset Acquisition [Line Items]            
Potential milestone payments $ 5,000